BRIEF-Bristol-Myers' Opdivo gets European Commission approval for relapsed or refractory CHL treatment

* European Commission approves Bristol-Myers Squibb's Opdivo

(nivolumab) for the treatment of adult patients with relapsed or

refractory classical hodgkin lymphoma after autologous stem cell

transplant and treatment with brentuximab vedotin

Read more